Selenium supplementation,baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial |
| |
Authors: | Duffield-Lillico A J,Dalkin B L,Reid M E,Turnbull B W,Slate E H,Jacobs E T,Marshall J R,Clark L C Nutritional Prevention of Cancer Study Group |
| |
Affiliation: | Arizona Cancer Center, Tucson, USA. |
| |
Abstract: | OBJECTIVE: To present the results (to January 1996, the end of blinded treatment) of the Nutritional Prevention of Cancer (NPC) Trial, a randomized trial of selenium (200 micro g daily) designed to test the hypothesis that selenium supplementation (SS) could reduce the risk of recurrent nonmelanoma skin cancer among 1312 residents of the Eastern USA. MATERIALS AND METHODS: Original secondary analyses of the NPC to 1993 showed striking inverse associations between SS and prostate cancer incidence. A subsequent report revealed that this effect was accentuated among men with the lowest baseline plasma selenium concentrations. The effects of treatment overall and within subgroups of baseline prostate-specific antigen (PSA) and plasma selenium concentrations were examined using incidence rate ratios and Cox proportional hazards models. RESULTS: SS continued to significantly reduce the overall incidence (relative risk and 95% confidence interval) of prostate cancer (0.51, 0.29-0.87). The protective effect of SS appeared to be confined to those with a baseline PSA level of
|
| |
Keywords: | selenium prostate cancer chemoprevention incidence risk PSA |
本文献已被 PubMed 等数据库收录! |
|